title: [Clinical evaluation of cefmenoxime and cefsulodin in chronic complicated urinary tract infections].
abstract: To patients with chronic complicated urinary tract infections (UTI) which were in compliance to the UTI standard, cefmenoxime (CMX) was given singly or in combination with cefsulodin (CFS) and efficacies of the respective preparations were examined. Of 53 patients examined, 40 were given CMX alone while 13 were given a combined preparation of CMX and CFS. Results are summarized as follows. With respect to the general clinical effects, 7 patients given CMX alone were markedly improved, 21 improved and 12 unchanged indicating an efficacy rate of 70%. In case of the CMX-CFS combined administration, 2 patients were markedly improved, 7 improved and 4 unchanged giving an efficacy rate of 69%. As for the bacteriological effects, 38 of 54 strains isolated from the patients given CMX alone were eliminated, 4 decreased, 12 unchanged and 15 substituted. Of 16 strains isolated from the patients given the CMX-CFS combined preparation, 4 were eliminated, 2 unchanged and 3 substituted. Thus, incidence of bacterial substitution was low in the combination treatment. The combination of CMX and CFS was more inhibitory to P. aeruginosa than CMX alone. Regarding side-effects, drug eruption was observed in one of the 53 patients and slight elevation of GOT and GPT was recognized in another.
authors.forename: Y
authors.initials: Y
authors.lastname: Shiraiwa
authors.forename: O
authors.initials: O
authors.lastname: Yamaguchi
authors.forename: K
authors.initials: K
authors.lastname: Ito
authors.forename: Y
authors.initials: Y
authors.lastname: Kuma
authors.forename: S
authors.initials: S
authors.lastname: Hozumi
authors.forename: K
authors.initials: K
authors.lastname: Kumakawa
authors.forename: H
authors.initials: H
authors.lastname: Ishiwata
authors.forename: M
authors.initials: M
authors.lastname: Arai
authors.forename: T
authors.initials: T
authors.lastname: Hirai
authors.forename: I
authors.initials: I
authors.lastname: Kumagai
mesh_terms: D000328:Adult; D000368:Aged; D015281:Cefmenoxime; D002439:Cefotaxime / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002441:Cefsulodin / Q000008:administration & dosage* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D014552:Urinary Tract Infections / Q000188:drug therapy*
chemical_list: D015281:Cefmenoxime; D002439:Cefotaxime; D002441:Cefsulodin